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Immunotherapy for glioblastoma: a long and winding road 
 
There has traditionally been discomfort with our current strategies to treat patients with 
gliomas, not only because their efficacy has remained limited despite undisputable 
progress, but also because a cure using a conventional combination of surgery, 
radiation therapy, and chemotherapy is still a distance away. This is, at least in theory, 
different for immunotherapy. In fact, clinical trials of immunotherapy, including various 
courageous local treatment approaches, have a long tradition in neurological surgery 
throughout the world. Accordingly, there are ongoing efforts to understand and 
circumvent the immunosuppression associated with glioblastoma and to design novel, 
more effective, but safe strategies of immunomodulation. 
In the present issue of Neuro-Oncology, Rodrigues and colleagues (1) report that 
human monocytes from healthy donors acquire a myeloid-derived suppressor cell 
(MDSC) phenotype when co-cultured with human glioblastoma cells. Glioblastoma-
conditioned monocytes exhibited reduced CD14 expression but increased expression of 
various immunosuppressive molecules, interleukin 10, transforming growth factor-β, and 
B7-H1; decreased phagocytic ability; and increased ability to induce apoptosis in 
activated lymphocytes. Direct contact between monocytes and glioblastoma cells was 
necessary for the complete induction of this phenotype. Moreover, the authors found 
elevated numbers of circulating MDSCs in the peripheral blood of glioblastoma patients, 
suggesting that these cells contribute to the cellular immunosuppression characteristic 
of glioblastoma. 
Dendritic cell-based therapies are currently the most widely applied cellular 
immunotherapy for glioblastoma, although no controlled trial has been performed so far. 
Using a murine glioma model, the laboratory of G. Finocchiaro demonstrated that the 
intratumoral injection of pulsed dendritic cells increased survival significantly, either per 
se or in combination with subcutaneously administered dendritic cells. Further 
experiments suggested that intratumoral pulsed dendritic cells potentiated the anti-
tumor immune responses elicited by subcutaneous dendritic cells by proimmune 
modulation of cytokines in the tumor microenvironment, a decrease of regulatory T 
cells, or a direct inhibition of tumor proliferation by tumor necrosis factor- (2). 
Finally, a third paper in this issue reports the results of a phase II trial in which 34 
patients with recurrent glioblastoma were treated with intratumoral CpG oligonucleotides 
administered intratumorally via convection-enhanced delivery (3). Treatment was well 
tolerated, but progression-free survival at 6 months was only 19%. One partial response 
and 3 “minor responses” were observed. Predictors of a favorable response to this 
treatment await identification. 
Despite these modest steps ahead, we are still waiting for the first breakthrough in the 
field of immunotherapy. Yet the field appears to be experiencing a revival, in part due to 
the heightened attention received by the vaccination strategy targeting mutant 
epidermal growth factor receptor  in patients with glioblastoma (4). 
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